Extreme hypofractionation for early prostate cancer: Biology meets technology.

Détails

ID Serval
serval:BIB_60D37AE2B2B5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Extreme hypofractionation for early prostate cancer: Biology meets technology.
Périodique
Cancer treatment reviews
Auteur(s)
De Bari B., Arcangeli S., Ciardo D., Mazzola R., Alongi F., Russi E.G., Santoni R., Magrini S.M., Jereczek-Fossa B.A.
Collaborateur(s)
on the behalf of the Italian Association of Radiation Oncology (AIRO)
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
11/2016
Peer-reviewed
Oui
Volume
50
Pages
48-60
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The aim of this review is to present the available radiobiological, technical and clinical data about extreme hypofractionation in primary prostate cancer radiotherapy. The interest in this technique is based on the favourable radiobiological characteristics of prostate cancer and supported by advantageous logistic aspects deriving from short overall treatment time. The clinical validity of short-term treatment schedule is proven by a body of non-randomised studies, using both isocentric (LINAC-based) or non-isocentric (CyberKnife(®)-based) stereotactic body irradiation techniques. Twenty clinical studies, each enrolling more than 40 patients for a total of 1874 treated patients, were revised in terms of technological setting, toxicity, outcome and quality of life assessment. The implemented strategies for the tracking of the prostate and the sparing of the rectal wall have been investigated with particular attention. The urinary toxicity after prostate stereotactic body irradiation seems slightly more pronounced as compared to rectal adverse events, and this is more evident for late occurring events, but no worse as respect to conventional fractionation schemes. As far as the rate of severe acute toxicity is concerned, in all the available studies the treatment was globally well tolerated. While awaiting long-term data on efficacy and toxicity, the analysed studies suggest that the outcome profile of this approach, alongside the patient convenience and reduced costs, is promising. Forty-eight ongoing clinical trials are also presented as a preview of the expectation from the near future.

Mots-clé
Disease-Free Survival, Dose Hypofractionation, Humans, Male, Prostatic Neoplasms/radiotherapy, Radiation Injuries/epidemiology, Radiosurgery/methods, Rectal Diseases/epidemiology, Treatment Outcome, Urologic Diseases/epidemiology
Pubmed
Création de la notice
14/02/2017 11:48
Dernière modification de la notice
20/08/2019 14:18
Données d'usage